An open label, multi-centre, non-randomized, single arm study to evaluate the safety and efficacy of APCEDEN? [Dendritic Cell (DC) immunotherapy] in patients with refractory solid malignancies, on symptomatic treatment. - ATESST (Apceden Therapy: Efficacy and Safety in Solid Tumors)

Trial Profile

An open label, multi-centre, non-randomized, single arm study to evaluate the safety and efficacy of APCEDEN? [Dendritic Cell (DC) immunotherapy] in patients with refractory solid malignancies, on symptomatic treatment. - ATESST (Apceden Therapy: Efficacy and Safety in Solid Tumors)

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Apr 2017

At a glance

  • Drugs Autologous dendritic cell immunotherapy - APAC Biotech (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ATESST; ATTEST
  • Sponsors APAC Biotech; Semler Research Center
  • Most Recent Events

    • 13 Apr 2017 New trial record
    • 05 Apr 2017 Results published in an APAC Biotech Media Release
    • 05 Apr 2017 Dr. P P Bapsy was a Principal investigator of this trial, as reported in an APAC Biotech media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top